IBRANCE 100 mg hard capsules clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA
This study compares two common breast cancer medicines, Kisqali and IBRANCE, for advanced hormone receptor-positive, HER2-negative or HER2-enriched breast cancer. It looks at how well they stop the cancer from growing and aims to see if one is better than the other.
For: Patients with advanced hormone receptor-positive/HER2- negative/HER2-Enriched breast cancerSpain · Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study
This study looks at new ways to treat advanced soft tissue sarcoma, a type of cancer. It uses special tests to check for changes in cancer cells and aims to find the best medicine for each person, making sure these tests are practical and quick enough.
For: Unresectable locally advanced and/or metastatic soft-tissue sarcomaFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1 /2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of amcenestrant (SAR439859 ), administered orally as monotherapy, then in combination with other anti-cancer therapies in postmenopausal women with estrogen receptor-positive advanced breast cancer
This study looks at a new drug, amcenestrant, for postmenopausal women with advanced breast cancer. It tests its safety and how well it works, both alone and with other common cancer medicines.
For: CancerBelgium · Spain